Mounjaro, Zepbound shortage eases
Mounjaro, Zepbound shortage eases as supplies of weight loss drug rebound
Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit cheaper copycat versions.
Mounjaro and Zepbound shortages over, declares FDA
The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli Lilly’s popular weight loss medication Zepbound and diabetes drug Mounjaro.
Mounjaro is here and it’s the ‘King Kong’ of weight loss jabs, but there’s a catch...
The NHS plans to roll out Mounjaro, a weight-loss jab that can help users lose up to a quarter of their body weight, making it more potent than Ozempic. Anna Magee explains how to choose the best opti
Lilly’s Tirzepatide No Longer on FDA Drug Shortage List
BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes and weight loss drugs are gaining market share as manufacturing continues to expand,
NHS to roll out Mounjaro weight loss jab to 1.6 million patients
In a phased rollout, the jabs eventually will be offered to those with a BMI of 35 or more and weight-related health problems
Eli Lilly’s weight-loss drug no longer in shortage, FDA says
The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug Administration announced Wednesday.
Eli Lilly’s Weight-Loss, Diabetes Drug Shortages Are Over, FDA Says
The FDA declared the end to shortages of Zepbound and Mounjaro. That could mean new restrictions on pharmacies making custom-made versions.
Lilly weight-loss drug copycats dealt blow as shortage ends
Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the U.S., threatening to upend the many knockoffs that became popular when patients couldn’t find the brand-name medicines.
Lilly's weight-loss drug removed from FDA's shortage list
The U.S. Food and Drug Administration removed Eli Lilly's blockbuster weight-loss and diabetes drugs from its shortage list late on Wednesday, likely piling pressure on firms selling cheaper versions known as compounded drugs.
Mounjaro and Zepbound Are No Longer in Shortage, F.D.A. Says
The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
NHS proposes phased launch for Eli Lilly’s Mounjaro
The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...
National Health Executive1h
Mounjaro: NICE consults on NHSE proposals for ’unprecedented’ obesity drug roll-out
Tirzepatide was granted approval from the Medicines and Healthcare products Regulatory Agency last November, while NICE ...
Mounjaro and Zepbound no longer in shortage
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
FiercePharma17h
NHS England proposes phased rollout for Eli Lilly's star obesity drug
While Mounjaro was cleared for use in England last year, Lilly put its launch on hold until its pre-filled injection device, ...
Facebook has become the place to sell leftover Ozempic, other weight loss drugs — as NYC sellers take advantage of shortages and high prices
God knows what volume they’re actually selling. And who knows? You’re just taking it,” one expert told The Post.
Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
Eli Lilly (NYSE:LLY) investing $4.5B to create Lilly Med Foundry, with goal of faster drug pipeline and scaling molecules to medicines. Stock outlook mixed.
Eli Lilly to build $4.5 billion research and manufacturing center to propel drug pipeline
Lilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer’s disease, ALS and other brain diseases, CEO David Ricks said.